IKT

Inhibikase Therapeutics, Inc.

2.15 USD
-0.10 (-4.44%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Inhibikase Therapeutics, Inc. stock is down -15.69% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 March’s closed higher than February.

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD.